港股異動 | 藥明巨諾-B(2126.HK)尾盤炒起 一度大漲逾8%
格隆匯7月16日丨藥明巨諾-B(2126.HK)尾盤一度大漲超8%,現報23.75港元,成交額為1.36億港元,總市值95.4億港元。格隆匯文章《如何看待細胞治療火熱下的藥明巨諾-B(2126.HK)?》提到,對於藥明巨諾而言,無論是在血液瘤上即將獲批的relma-cel還是已經在實體瘤領域的佈局,都在證明其強勁的研發實力。目前藥明巨諾已經正在推進降成本的戰略,未來會系統性地大規模降低成本。這些都將會為藥明巨諾未來業績爆發提供有利保障。作為為新興的創新藥企,藥明巨諾受到包括中金以及興業證券等多家券商機構看好。其中,中金證券給予藥明巨諾“跑贏行業”評級,目標價43.69港元,較藥明巨諾目前股價存在94.61%的上行空間。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.